These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 2170549)
1. [Clinical value of a new serum tumor marker CA602 in ovarian cancers]. Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549 [TBL] [Abstract][Full Text] [Related]
2. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases]. Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340 [TBL] [Abstract][Full Text] [Related]
3. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers]. Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967 [TBL] [Abstract][Full Text] [Related]
4. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes]. Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409 [TBL] [Abstract][Full Text] [Related]
5. [Relationship between tumor markers and clinical symptoms in ovarian cancer]. Yakushiji M; Nishimura H Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760 [TBL] [Abstract][Full Text] [Related]
6. [The usefulness and limitation of sugar antigen in ovarian cancers--with special reference to a new tumor marker, CA54/61]. Nozawa S Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1147-51. PubMed ID: 2499263 [TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer]. Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320 [TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors]. Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243 [TBL] [Abstract][Full Text] [Related]
9. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors]. Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801 [TBL] [Abstract][Full Text] [Related]
10. [Tumor markers of ovarian cancer]. Nozawa S Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759 [TBL] [Abstract][Full Text] [Related]
11. CA54/61 as a marker for epithelial ovarian cancer. Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381 [TBL] [Abstract][Full Text] [Related]
12. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289 [TBL] [Abstract][Full Text] [Related]
14. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers]. Kataoka A; Yakushiji M Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782 [TBL] [Abstract][Full Text] [Related]
15. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). Nozawa S; Yajima M; Sasaki H; Tsukazaki K; Aoki D; Sakayori M; Udagawa Y; Kobayashi T; Sato I; Furusako S Jpn J Cancer Res; 1991 Jul; 82(7):854-61. PubMed ID: 1715339 [TBL] [Abstract][Full Text] [Related]
16. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies. Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081 [TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis]. Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125. Suzuki M; Sekiguchi I; Tamada T Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620 [TBL] [Abstract][Full Text] [Related]
19. [New technology of diagnosis of ovarian cancer]. Terashima Y Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169 [TBL] [Abstract][Full Text] [Related]
20. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker]. Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]